Pharmacoeconomics

Papers
(The H4-Index of Pharmacoeconomics is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?111
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”104
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling64
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment64
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment57
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting53
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children49
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis43
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy39
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment36
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment33
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based 32
Advancing Methods to Measure and Reward Healthcare Innovation32
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation32
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review31
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review30
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA30
Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer29
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)28
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions28
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy28
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned28
Bayesian Meta-Analysis: A Practical Introduction28
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling26
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review25
A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons25
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada25
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS25
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States25
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies25
0.059156179428101